ERBB2 and breast carcinoma: While these agents have shown efficacy in the treatment of HER2 overexpressing breast cancer, not all HER2- positive cancers respond even initially to these drugs, and the development of trastuzumab and lapatinib resistance is an additional clinical problem [42].